Skip to main content

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Stock Forecast

Data as of May 7, 2026

Healthcare · Current price $0.85 (-3.04%)

Consensus Target
Upside
Analysts
8
Rating
Buy(2.25)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy2
Hold2
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

RVPH vs Sector & Market

MetricRVPHHealthcare AvgLarge Cap Avg
Analyst Rating2.252.242.41
Analyst Count8818
Target Upside+1148.8%+14.9%
P/E Ratio0.007.0631.92

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$5M$5M$5M4
2027-12-31$137M$137M$137M4
2028-12-31$186M$186M$186M2
2029-12-31$379M$379M$379M1
2030-12-31$158M$158M$158M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-3.81$-2.26$-1.384
2027-12-31$-1.30$-0.95$-0.593
2028-12-31$-1.20$-0.80$-0.402
2029-12-31$-0.77$-0.77$-0.771
2030-12-31$0.14$0.14$0.141

Frequently Asked Questions

What is the analyst consensus for RVPH?

The consensus among 8 analysts covering Reviva Pharmaceuticals Holdings, Inc. (RVPH) is Buy with an average price target of N/A.

How many analysts cover RVPH?

8 analysts have issued ratings for Reviva Pharmaceuticals Holdings, Inc. in the past 12 months.

Is RVPH a buy or sell right now?

Based on 8 analyst ratings, RVPH has a consensus rating of Buy (2.25/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for RVPH?

Analysts estimate RVPH will report EPS of $-2.26 for the period ending 2026-12-31, with revenue estimated at $5M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.